AIM:To evaluate nanosilver eye patches versus Atrauman nanosilver dressings for ocular surface trauma.METHODS:This randomized non-inferiority trial(November 2024-April 2025)enrolled 60 patients assessed pre-treatment ...AIM:To evaluate nanosilver eye patches versus Atrauman nanosilver dressings for ocular surface trauma.METHODS:This randomized non-inferiority trial(November 2024-April 2025)enrolled 60 patients assessed pre-treatment and on days 1,7,and 14 post-treatment.The patients were then randomized into treatment(nanosilver eye patches)and control groups(Atrauman nanosilver dressings).Outcomes included wound healing,comfort(Ocular Comfort Index,OCI),and safety.Statistical analyses used t-tests,non-inferiority tests,and Chi-square tests.RESULTS:Patient baseline characteristics were comparable between groups,with a mean age of 60.633±10.934 in the treatment group versus 64.933±9.606 in controls,and similar gender distribution(20/10 vs 17/13 male/female).Both groups showed comparable baseline OCI scores(treatment group:6.100±2.187 vs control group:6.267±2.303,P=0.775).Following treatment,scores increased significantly at day 1(treatment group:9.367±2.251;control group:9.067±2.212,both P<0.001 vs baseline).Marked improvement was observed by day 7(treatment group:4.067±1.929;control group:3.900±1.918,P<0.001 vs baseline),with complete resolution at day 14(0.467±0.860 vs 0.467±1.008,P<0.001).The non-inferiority criterion was met.The treatment group showed greater improvement in Grade A wound healing rates(76.67%to 93.33%)compared to controls(80.00%to 86.67%)between 1 and 7d post-treatment.By 14d posttreatment,all patients achieved Grade A healing in both groups,with no Grade C cases observed throughout the study period.No adverse events were reported.CONCLUSION:Nanosilver eye patches are non-inferior to Atrauman dressings,offering effective,safe emergency care for ocular trauma.展开更多
基金Supported by High and New Technology Project of Hainan Key Research and Development Plan(No.ZDYF2024GXJS032)Health Care Special Project of PLA Logistics Research Fund(No.23BJZ37)Scientific Research Project of Health Industry in Hainan Province(No.22A200351).
文摘AIM:To evaluate nanosilver eye patches versus Atrauman nanosilver dressings for ocular surface trauma.METHODS:This randomized non-inferiority trial(November 2024-April 2025)enrolled 60 patients assessed pre-treatment and on days 1,7,and 14 post-treatment.The patients were then randomized into treatment(nanosilver eye patches)and control groups(Atrauman nanosilver dressings).Outcomes included wound healing,comfort(Ocular Comfort Index,OCI),and safety.Statistical analyses used t-tests,non-inferiority tests,and Chi-square tests.RESULTS:Patient baseline characteristics were comparable between groups,with a mean age of 60.633±10.934 in the treatment group versus 64.933±9.606 in controls,and similar gender distribution(20/10 vs 17/13 male/female).Both groups showed comparable baseline OCI scores(treatment group:6.100±2.187 vs control group:6.267±2.303,P=0.775).Following treatment,scores increased significantly at day 1(treatment group:9.367±2.251;control group:9.067±2.212,both P<0.001 vs baseline).Marked improvement was observed by day 7(treatment group:4.067±1.929;control group:3.900±1.918,P<0.001 vs baseline),with complete resolution at day 14(0.467±0.860 vs 0.467±1.008,P<0.001).The non-inferiority criterion was met.The treatment group showed greater improvement in Grade A wound healing rates(76.67%to 93.33%)compared to controls(80.00%to 86.67%)between 1 and 7d post-treatment.By 14d posttreatment,all patients achieved Grade A healing in both groups,with no Grade C cases observed throughout the study period.No adverse events were reported.CONCLUSION:Nanosilver eye patches are non-inferior to Atrauman dressings,offering effective,safe emergency care for ocular trauma.
